HC Wainwright Issues Pessimistic Forecast for Repare Therapeutics (NASDAQ:RPTX) Stock Price

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) had its target price reduced by analysts at HC Wainwright from $10.00 to $5.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 334.78% from the company's current price.

Several other research analysts have also issued reports on the company. Bloom Burton downgraded Repare Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, January 10th. Stifel Nicolaus lowered their price objective on Repare Therapeutics from $9.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Finally, Lifesci Capital reaffirmed a "market perform" rating on shares of Repare Therapeutics in a research note on Friday, December 13th.

Repare Therapeutics Price Performance

NASDAQ RPTX traded up $0.01 during trading hours on Friday, reaching $1.15. The company's stock had a trading volume of 351,103 shares, compared to its average volume of 292,707. The firm has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $2.40. Repare Therapeutics has a 52 week low of $1.06 and a 52 week high of $5.66. The stock has a market cap of $48.89 million, a P/E ratio of -0.58 and a beta of 0.87.

Remove Ads

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. On average, research analysts expect that Repare Therapeutics will post -2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its position in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock valued at $29,000 after purchasing an additional 7,800 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Repare Therapeutics by 204.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock valued at $45,000 after buying an additional 23,127 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock worth $46,000 after buying an additional 11,000 shares in the last quarter. Stifel Financial Corp grew its position in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company's stock worth $178,000 after buying an additional 13,800 shares during the period. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Repare Therapeutics during the 4th quarter worth approximately $104,000. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.